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Objective(s): Blocking of vascular endothelial growth factor (VEGF) plays a pivotal role in inhibition 
of metastasis and is a target for development of anti-angiogenic agents. In this study, a peptide-based 
vaccine was designed and its potential for induction of humoral immune responses, generation of 
neutralizing antibodies, inhibition of tumor growth and metastasis was determined.
Materials and Methods: With online bioinformatics tools, a fragment of the VEGF-A was selected for 
a peptide-based vaccine. To enhance its antigenicity, the peptide was conjugated with Keyhole limpet 
hemocyanin and used to immunize mice. Then, the polyclonal anti-VEGF antibody titer was measured 
and its effect on proliferation of HUVEC cell line was investigated by MTT assay. Finally, we checked 
the effect of the peptide on tumor growth, metastasis, and survival rates in a mouse model of cancer.
Results: The bioinformatics analysis of the selected region confirmed dis-similarity of the peptide 
with any other human protein and its acceptable antigenicity to stimulate a tumor-specific humoral 
response. Anti-VEGF antibody titers were significantly greater in vaccinated mice than in controls. IgG 
antibody from mice immunized with recombinant VEGF-A inhibited HUVEC proliferation (P<0.0001). 
Tumors in vaccinated mice were significantly smaller than those in controls. Moreover, metastasis was 
reduced and survival rates increased in the vaccinated group.
Conclusion: Production of high-titer antibody against the peptide vaccine indicated that the peptide 
has the potency to be used as a peptide-based vaccine for humoral inhibition of tumor growth and 
metastasis. The efficacy of the peptide should be further tested in primate models.
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Introduction
Angiogenesis is an essential process in the 
development and growth of tumor tissue. In the absence 
of this process, tumors will not grow beyond two mm3 in 
size. Thus, inhibition of angiogenesis is a basic strategy 
in cancer vaccination approaches (1, 2). Sprouting of 
angiogenesis is regulated by various key agents such 
as vascular endothelial growth factor (VEGF), which is 
highly expressed and continuously secreted from most 
solid tumors, and demonstrates both autocrine and 
endocrine characteristics (3-5). Therefore, inhibition 
of angiogenesis via blockage of VEGF signaling could 
suppress promotion of solid tumors (6). Currently, 
several anti-angiogenic approaches, especially anti-
VEGF drugs have been approved by international 
committees for certain advanced cancers; some have 
been applied in clinical trials, while others are under 
further evaluation or await approval (2). It has been 
previously shown that the functionality of VEGF/
VEGFR could be directly blocked by various antibodies 
such as Bevacizumab (Avastin®) and Ramucirumab 
(Cyramza®), or trapped by soluble VEGF receptors such 
as Aflibercept (Zaltrap®) (7, 8), or indirectly blocked 
by inhibiting receptor activity by specific antibodies 
or administration of the inhibitors of tyrosine kinase 
receptor. In this regard, clinical application of Sunitinib 
(Sutent®), Sorafenib (Nexavar®), and Pazopanib 
(Votrient®) has been approved for various tumors (9). 
Bevacizumab, the first humanized monoclonal antibody 
against VEGF-A, was approved by the FDA in 2004. 
Administration of Bevacizumab, in combination with 
other chemotherapy agents, showed acceptable anti-
tumor efficacy for many solid tumors (10). 
Among the recent approaches in cancer 
immunotherapy, passive immunotherapy including 
application of blocking monoclonal antibodies or 
trapping soluble receptors, merely provides a short-
lived response, requiring repeated administration of 
the component; however, active immunotherapy that 
engages the host immune response is highly desirable, 
resulting in sustained induction of anti-cancer effects 
(11, 12). Anti-angiogenic vaccines could be produced 
based on DNA, peptide, or protein-based structures. 
Recently, studies focused on VEGF and its receptors as 
desirable targets to block angiogenesis.
Activation of patients own immune responses 
would likely introduce less toxicity and side effects 
than conventional chemotherapeutic medications. 
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Therefore, it seems that application of protein- or 
peptide-based vaccines, in combination with mild doses 
of radiotherapy, chemotherapy, or other anti-angiogenic 
agents, may suppress tumor size, growth rate, and 
metastasis (12-16). 
In the present study, we investigated the anti-angiogenic 
efficacy of a VEGF-A peptide-based vaccine in mice. 
Materials and Methods
Immunoinformatics analysis and peptide design
Amino acid sequences of human VEGF-A (hVEGF165 and 
hVEGF121) and mouse VEGF-A (mVEGF164 and mVEGF120) 
were retrieved from the UniProt database. Among all 
isoforms of human VEGF-A, human VEGF165 (P15692-4) 
and VEGF121 (P15692-9) were used for peptide design, 
because they were regarded as major isoforms of 
human VEGF-A, and showed no significant differences 
with the sequences of mouse VEGF-A164 (Q00731-
2) and VEGF-A120 (Q00731-3) (2). Mega-4 alignment 
software was used to align the isoforms and to find the 
conserved and similar peptide sequences of human and 
mice. Among the protected areas, an extracellular 41-
mer peptide was selected for determination of T- and 
B-cell epitopes by Immune Epitope Database Analysis 
Resources (IEDB). The selected areas were also evaluated 
for immunogenicity, hydrophilicity, antigenicity, 
flexibility, and accessibility. Presuming the possible 
future application of this peptide in human vaccination 
studies, during sequence selection steps, we considered 
the major histocompatability complex (MHC) restriction 
concept, possible loading of this peptide onto common 
human leukocyte antigen (HLA) class I and II molecules, 
especially in the Iranian population with HLA-A*0201 
and HLA-DRB1* 1103/1104, respectively and its 
presentation to T cells. Non-overlapping characteristics 
of the selected sequence with human proteins were 
determined by protein BLAST. The peptide was then 
synthesized and attached to Keyhole limpet hemocyanin 
(KLH) at Selleckchem Company (Selleckchem, USA). 
Animals 
Twenty 6-8-week-old female BALB/c mice were 
obtained from the animal breeding laboratory of Iran 
University of Medical Sciences (IUMS), Tehran, Iran, 
and kept for one week at the animal house to become 
adapted to study conditions. All procedures were 
performed under the rules and guidance of the Animal 
Care Ethical Committee at Isfahan University of Medical 
Sciences. Mice were divided to four groups of five mice 
each. The groups were: (1) the vaccine group, which was 
vaccinated with the KLH-conjugated VEGF-A peptide 
and challenged with breast cancer-inducing 4T1 cells 
to evaluate the prophylactic potential of the peptide, 
(2) the tumor group, which was injected only with 
4T1 cells to evaluate the ability of the injected cells to 
induce tumors, (3) the antibody control group, which 
was vaccinated only with the KLH-conjugated peptide 
to evaluate antibody development, and (4) the negative 
control group, which received only phosphate-buffered 
saline (PBS).
Immunization of mice and production of polyclonal 
antibody 
To induce humoral immune responses, the vaccine 
and antibody control group mice were injected with 100 
μl of a 1 μg/μl solution of the KLH-conjugated peptide 
without adjuvant on days 1 of weeks 1, 3, and 5 as 
previously described (17). To boost the antibody titer, the 
antibody control group received another immunization 
on day 1 of week 11, too. Sera was collected from all 
mice before and two weeks after immunizations and 
stored at -20 °C. 
Total IgG was isolated from the antibody control 
mice sera using an Antibody Purification Kit (Abcam, 
UK) containing protein G-coupled resin, according to 
the manufacturer’s instructions. The quality of the 
purification step was determined by SDS-PAGE and 
silver nitrate staining (18).
Mouse tumor model
To determine the prophylactic potency of the 
conjugated peptide, the vaccine and tumor groups 
were inoculated subcutaneously four days after the 
final immunization with 5×105 4T1 breast cancer cells 
as previously described (19). In brief, the 4T1 mouse 
breast cancer cells were cultivated in RPMI media 
supplemented with 10% fetal bovine serum (FBS). Mice 
were inoculated subcutaneously into four mammary fat 
pads on the right side with 5×105 4T1 cells suspended 
in 100 μl of PBS. Body weights, clinical symptoms, 
appearance of fur, and tumor size were recorded every 
other day. Tumor sizes were calculated using the formula: 
length×(width)2×0.5 as previously described (19). 
Measurement of serum anti-VEGF titer 
An enzyme-linked immunosorbant assay (ELISA) 
was used to measure the polyclonal anti-VEGF 
antibody titer in mice sera. First, 0.5 mg of peptide was 
conjugated to 2 mg of bovine serum albumin (BSA) 
using glutaraldehyde reagent as described (20, 21). 
After dialysis, the final product was analyzed by SDS-
PAGE and silver nitrate staining (17-22). For ELISA 
development, microtiter plates (Maxisorb, Costar, USA) 
were coated with 100 µl (2 μg/well) of BSA-conjugated 
peptide in 0.1 M sodium bicarbonate buffer (pH 9.6) 
overnight at 4 °C. After washing the wells three times 
with PBS containing 0.05% Tween 20 (PBS-T), the 
plates were blocked with 2% casein for 2 hr. The plates 
were then washed twice and 100 μl of serially-diluted 
serum samples were added and incubated for 2 hr. 
The wells were then washed five times, and 100 μl of 
horseradish peroxidase-conjugated sheep anti-mouse 
IgG (Sigma, USA) were added to each well and incubated 
for 1 hr. The wells were then washed five times, and 100 
μl of TMB (3,3′,5,5′-Tetramethylbenzidine) substrate 
were added. After 15 min of incubation in the dark, the 
reaction was stopped with 100 μl of 2 M sulfuric acid 
and the absorbance was read at 450 nm against a 630 
nm reference filter on an ELISA reader. All incubations 
were performed at 37 °C, except for the coating step. 
Evaluation of inhibitory effects of polyclonal 
antibodies on HUVEC 
To determine the inhibitory effects of the raised 
polyclonal antibodies on human VEGF receptor 
2 (VEGFR2)-positive cells, human umbilical vein 
endothelial cells (HUVECs) were cultivated in 96-well 
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plates (1000 cells/well) with DMEM/F12 medium 
containing 2% FBS and incubated at 37 °C in 5% CO2 
for 24 hr. Three types of treatments were used. The 
negative control cells received 0, 25, 50, or 100 ng/ml of 
recombinant VEGF-A (Sigma, USA). The positive control 
cells, in addition to VEGF-A, received 100 ng/ml of anti-
VEGF monoclonal antibody (Abnova, Taiwan). The test 
cells, in addition to VEGF-A, received various titers of 
purified IgG that were isolated from immunized mice. 
After 48 hr, cell proliferation was evaluated by MTT 
assay. MTT was added at a concentration of 0.5 mg/ml 
to each well, and plates were incubated in 5% CO2 for 4 
hr at 37 °C. Formazan crystals were dissolved by adding 
dimethyl sulfoxide, and after 15 min of incubation at 37 
°C the absorbance was measured at 570 nm on a micro 
plate reader.
Histology
Hematoxylin and Eosin (H&E)-stained paraffin-
embedded tissues were histologically examined for 
metastases. Three animals from each group were 
euthanized at the end of week 9 and brains, livers, and lungs 
were removed, fixed in 4% paraformaldehyde, stained, 
and examined. Tumor metastases were examined in three 
random sections and the morphological parameters, 
indicating metastasis severity were scored from 0-3 (19). 
Statistical analyses
The student’s t-test was used to analyze specific 
IgG titers and mice body weights. The Mann-Whitney 
test was used to compare the tumor sizes between the 
vaccine and control groups. Survival time was analyzed 
by the Kaplan-Meier method and the groups were 
compared by the log-rank test. Findings were expressed 
as means±standard deviations (SDs). Results were 
considered significant if the P-value of the result was 
<0.05. All analyses were performed using SPSS version 
20.0 (Armonk, New York, USA) and GraphPad Prism 6.0 
software (La Jolla, CA, USA). 
Results
Immunoinformatics data analysis 
The immunoinformatics study indicated 
that the selected 41-mer peptide 
(SNITMQIMRIKPHQGQHIGEMSFLQHNKCECRPKKDRARQE) 
was sufficiently hydrophilic and antigenic to stimulate 
the immune system. Based on analysis that was shown 
in Figure 1, selected sequence in addition to highest 
rank for B cell epitope has MHC I and II binding epitopes 
(Figure 1).
Production and titration of anti-peptide polyclonal 
antibody 
In the antibody control group mice, after vaccination 
with KLH-conjugated peptide, the absorbance at 450 
nm was significantly greater at weeks 10 and 13 than on 
initial day of the first week in the 1/100 diluted pooled 
sera (P<0.05 and P<0.005, respectively), indicating that 
the anti-VEGF polyclonal antibody titer was significantly 
greater at weeks 10 and 13 than on day 1 (Figure 2). 
Sera were collected from the mice at 5, 7, and 9 weeks 
after inoculation of the tumor cells and peptide vaccine. 
Optical densities (ODs) of 1/100 dilutions of these sera 
were analyzed (Figure 3). At all three time points, the 
ODs of the vaccine and tumor groups were significantly 
greater than those of the negative control group (P=0.05 
and 0.005, respectively), indicating greater antibody 
titers in the vaccine and tumor groups than in the 
negative control group. 
Effects of polyclonal antibody on HUVEC proliferation 
We investigated the effect of purified immunoglobulins 
from immunized mice sera on proliferation of VEGF-







Figure 1. T-cell epitope prediction in human using Immune Epitope 
Database Analysis Resource (IEDB-AR) 
The major histocompatability complex (MHC) I and II were restricted 
to human leukocyte antigen A*0201 (HLA-A*0201) (Red) and HLA-
DRB1* 1103/1104 (Highlight). The percentile rank cut off point was 










Figure 2. Absorbance at 450 nm of pooled sera from antibody 
control group mice diluted 1/100, 1/500, 1/1000, and 1/10000 on 
the day of immunization (day 1 of week 1) and 10 and 13 weeks 







Figure 3. Optical densities of 1/100 dilutions of sera (means±SDs) 
from the tumor group and vaccine group mice, which were inoculated 
with 4T1 cells, and the negative control group, measured by ELISA 5, 
7, and 9 weeks after immunization (P=0.05, P=0.005, respectively)
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positive control, and test cells all received 50 ng/ml of 
recombinant VEGF-A. The positive control cells also 
received 300 ng/ml of anti-VEGF monoclonal antibody, 
and the test cells received 80 μg/ml IgG from immunized 
mice. Proliferation was set at 100% for the negative 
control cells. Proliferation in the positive control and 
test cells was significantly lower than in the negative 
controls (Figure 4, P<0.001 for both groups).
Inhibition of tumor growth in mice
After injection of 4T1 cells, tumor size was determined 
in the vaccine and tumor group up to eight weeks. From 
the second week on, tumors were larger in the tumor 
group than in the vaccine group, and this difference was 
statistically significant at eight weeks (P<0.001). No 
tumor growth was observed in the vaccine group from 
weeks 1-6 (Figure 5). 
Five weeks after inoculations with 4T1 cells, 
three mice from the vaccine and tumor groups were 
euthanized for tissues examination. Metastases were 
observed in the lung and liver tissues, primarily in the 
tumor group mice (Figure 6A and Table 1). In addition, 
primary tumors in the tumor group were significantly 
larger than those in the vaccine group (Figure 6B, 





Figure 4. Human umbilical vein endothelial cell proliferation 
inhibition was determined by MTT assay
The negative control cells received 50 ng/ml of recombinant vascular 
endothelial growth factor (VEGF)-A only.  The positive control cells 
received 50 ng/ml of recombinant VEGF-A plus 300 ng/ml of anti-
VEGF monoclonal antibody. The test cells received 50 ng/ml of 
recombinant VEGF-A plus 80 μg/ml total IgG that was isolated from 
immunized mice. Proliferation for the negative control cells was set at 
100%.  Growth was significantly less in both the positive control and 
















Figure 5. Tumor volumes in vascular endothelial growth factor 
(VEGF) peptide-vaccinated (vaccine group) and untreated (tumor 
group) mice 1-8 weeks after tumorigenesis with 4T1 cells
Table 1. Characterization of metastatic properties in lung and liver tissues. Vascularization, necrosis, inflammation, infiltration, and number of 




Mouse ID Metastatic 
Tissues 
Groups Vascularization* Necrosis** Inflammation*** Infiltration % No. of distinct histologically 
detectable metastasis 
31 Lung Vaccine 0 0 0 0% 0 
32   0 0 0 0% 0 
33   +1 +1 Mo+ 40% 3 
21  Tumor Only +1 0 Mo+ 40% 10 
22   +1 +3 Mo+ 70% 4 
23   +1 0 Mo+ 60% 1 
        
31 Liver Vaccine 0 0 0 0% 0 
32   0 0 0 0% 0 
33   0 0 PMN+ 40% 3 
21  Tumor Only +2 +2 PMN+ 10% 11 
22   +2 +1 0 5% 12 
23   +1 0 0 0 1 
  
*0 = absence of microscopic neoangiogenesis; 1= moderate neoangiogenesis
**0=no necrosis; =moderate; 2=severe
***0=no inflammatory mononuclear and polymorphonuclear cells; Mo+=inflammatory mononuclear cells; PMN+=inflammatory polymorphonuclear 
cells 
Infiltration %=percent of inflammatory cell infiltration
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Lung and liver tissues from the vaccine group and 
tumor group mice were examined by H&E staining and 
light microscopy. Five weeks after inoculation with 4T1 
cells, both lung and liver from the vaccine group mice 
appeared normal, while lung and liver tissues from the 
tumor group mice showed metastases, inflammation, 
necrosis, and infiltration of inflammatory cells. 
Following necropsy, all mice were examined for 
metastasis and any other pathological disorders. Fewer 
metastatic tumors and tumor-related pathologies were 
found in the lung and liver tissues of vaccine group than 
tumor group (Table 1). No metastasis was found in the 
brain tissue of either groups.  
Survival rates of the studied groups
The survival rates of the vaccine group mice were 
significantly greater than those of the tumor group mice 
(P<0.0001). All negative controls survived during the 
study (Figure 7). Notably, the vaccination steps did not 
show any side effects. So that, no significant changes 
were detected in behavior, feeding, body weight or 
appearance of the studied animals.
Discussion
Because growth, expansion, and survival of tumor 
cells depend on angiogenesis, thus inhibition of 
angiogenic pathways could be a crucial strategy in 
cancer treatment (23). Active immunotherapy and 
vaccine design against VEGF and its receptors still 
remain topics of interest as therapeutic approaches for 
inhibition of angiogenesis (24, 25). Nowadays, various 
tumor-associated therapeutic proteins have been 
applied to elicit tumor-specific immune responses. One 
commonly used safe method relies on administration 
of recombinant peptides in presence or absence of 
adjuvants. Although these peptides have been shown 
to induce tumor-targeted immune responses, it seems 
that the anti-cancer potential of such approaches is 
limited (26). In 2001, Wei et al. applied the first VEGF-
based cancer vaccine in the form of xenogenic DNA to 
evaluate its anti-tumoral effect on three different tumor 
models and observed that humoral immune response 
against VEGF could inhibit primary tumor growth (27). 
Kamstock et al. developed another xenogenic vaccine 
against VEGF and evaluated its efficacy in dogs with soft 
tissue sarcoma. In that study, DNA-liposome complexes 
were coupled with human VEGF165 and high antibody 
titers were achieved after immunization with the 
adjuvant-imbedded protein vaccine (28).
In another study, Rad et al. introduced the VEGF 
Kinoid vaccine based on human and murine VEGF 
isoforms. So that, a KLH-conjugated VEGF sequence was 
used for immunization, and after vaccination of the mice 
with Freund’s adjuvant, polyclonal anti-VEGF antibody 
was purified from the mice sera. Afterwards, they 
examined the inhibitory effect of polyclonal anti-VEGF 
on human colon carcinoma, as well as mouse and human 
rhabdosarcoma; consequently, they concluded that this 
approach achieved promising results for inhibition of 
metastasis (29). In another experiment, Gavilando et al. 
introduced CIGB-247 as a novel protein vaccine. They 
studied the immunogenicity of this protein in murine, rat, 
rabbit, and monkey models and reported no unfavorable 
hematological, biochemical, or histological side effects 
on the vital organs of the studied animals. This vaccine 
also did not show any side effects on normal behavior of 
the animals and demonstrated maintenance of desirable 
antibody titers after booster doses. This vaccine was a 
recombinant form of human VEGF, which was expressed 
in Escherichia coli and applied in parallel with small 
amounts of proteoliposome of the outer cell wall of 
Neisseria meningitidis as adjuvant. Immunization of 















Figure 6. Tumor metastasis. (A) Primary tumor and metastases in lymph nodes and lung in one tumor group mouse inoculated with 4T1 tumor 
cells. Five weeks after injection of 5×105 4T1 tumor cells in mice, in addition to the primary tumor (blue arrow), metastases to lung (black arrows) 







Figure 7. Survival rates of the negative control group, tumor group, 
and vaccine group. The tumor group and vaccine group mice were 
inoculated with 5×105 4T1 tumor cells. The negative control group 
mice received only phosphate-buffered saline (PBS) at the time of 
inoculation
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and increased animal survival rate and serum titer of 
anti-VEGF antibody (14-30). Afterwards, investigation 
of the safety and immunogenicity of CIGB-247 in human 
phase I clinical trial initiated and demonstrated some 
clinical benefits (31).  
Kaumaya et al. in 2010 developed a peptide vaccine 
consisting of synthetic peptides of VEGF as an antigen 
and T cell epitope of  the measles virus fusion protein 
(MVF) protein as an adjuvant. After evaluation of 
efficiency of this peptide vaccine on inhibition of 
VEGFR2 signaling pathway (32), Wang et al. used these 
synthetic peptide vaccines in murine ovarian cancer 
model, and the development of high titers of antibody 
against synthetic peptides was in line with inhibition of 
angiogenesis in primary tumor models (33).  
In 2013, Kyutoku et al. designed DNA vaccine for 
neutralizing VEGF. For enhancing the immunogenicity 
of vaccine, hepatitis B virus core (HBc) antigen was 
considered as an epitope carrier. HBc-VEGF vaccine was 
evaluated in murine with colon carcinoma and showed 
humoral immune response that reduced formation of 
new vessels (34).
Unlike the above studies, the peptide vaccine 
in our study was designed based on immunogenic 
structures. Hence, as expected, and as the results of 
the immunoinformatics analysis showed, the selected 
peptide, in addition to sufficient antigenicity and ability 
to stimulate the body’s immune system had the least 
similarity to other proteins and probably might cause 
fewer side effects.
Similar to experiments of Rad et al. in 2007, kinoid 
technology against VEGF was used. KLH was conjugated 
to the designed peptide to stimulate the immune system 
and overcome tolerance to VEGF, as a self-antigen. The 
MTT assay revealed that purified IgG from the peptide-
vaccinated mice inhibited VEGF-A-induced HUVEC 
proliferation, and this result was similar to the inhibitory 
effect of monoclonal anti-VEGF antibody. 
In this study, according to assessment in UniProt 
and other bioinformatics databases, we chose a 41-
mer peptide. This 41-mer sequence was selected from 
a conserved part of VEGF molecule that did not differ in 
the amino acid sequence between the human-VEGF and 
mouse-VEGF. The selected 41-mer peptide stimulated 
a specific humoral immune response against VEGF. We 
demonstrated that in silico-designed peptide vaccines 
can inhibit metastasis in vivo. In addition to monoclonal 
antibodies, such as Bevacizumab that have adverse side 
effects and require repeated administrations, cancer 
vaccines offer promise for cancer patients. 
Our results demonstrated that vaccination with a 
VEGF peptide might produce an antibody response and 
inhibit primary tumor growth and metastasis.
Although anti-VEGF antibody was produced in the 
tumor group mice, tumor growth was significantly lower 
in the vaccine group mice (P<0.001), and no tumor 
growth was observed in this group until seven weeks 
after inoculation (Figure. 5). In some studies, decreases 
in tumor growth required multiple immunizations and 
results were not significant. Gavilando et al. showed 
decreased tumor growth using six immunizations 
and three different adjuvants over 36 days following 
inoculation of mice with cancer cells (11), and Wang 
et al. showed decreased tumor growth using four 
immunizations with a VEGF peptide vaccine conjugated 
to measles virus fusion protein over 45 days after 
inoculation of mice with cancer cells (28).
To evaluate metastasis, the use of appropriate 
cancer cell lines with effective invasion and metastatic 
properties is crucial. Because the immune system plays 
an important role in the development and progression 
of tumor, we used BALB/c mice and 4T1 breast cancer 
cells, which are highly tumorigenic and invasive, and 
unlike most tumor models, can spontaneously migrate 
from the primary tumor in the mammary gland to distal 
sites including lymph nodes, liver, lung, brain, and bone 
(35, 36). 
In this study, by using 4T1 cancer cells, we found less 
metastasis, necrosis, inflammation, vascularization, and 
micro-metastatic clones in livers and lungs of the vaccine 
group than in the tumor group mice (data not shown). 
Our findings indicate that the antibody response could 
significantly inhibit metastasis, and the mice showed 
no metastatic markers. Moreover, no brain metastases 
were found in the six mice, which were sacrificed five 
weeks after tumor growth. However, metastasis to liver 
and lung was obviously severe in the tumor group.
Previous studies showed that multiple immunization 
and application of adjuvants could decrease the rate of 
metastasis and increase survival rate, and it could be 
due to antibody titer rise. Our study was relatively short 
due to the rapid appearance of tumors and metastases 
following a single injection with 4T1 cells. In future 
studies, we will further examine the effects of multiple 
immunizations and adjuvants. In addition, the presence 
of a T cell epitope also allowed us to assess immunologic 
memory. The low survival rates of the mice in this study 
did not allow sufficient time to observe changes in 
antibody titers.
Application of an appropriate treatment and 
considering an optimal strategy for inhibition of tumor 
growth is a crucial item in cancer therapy. Recent studies 
have shown that combination therapies, especially 
combination of immunotherapy with chemotherapy, 
and usage of immune checkpoint inhibitors can provide 
hopeful results in clinic (37, 38). In this regard, designing 
and employing of peptide-based vaccines sounds a 
promising strategy (39). Therefore, considering the 
time limitation for hindering possibility of metastasis, it 
seems that anti-angiogenic vaccination strategies such 
as immunization against VEGF might be a promising 
method following initial diagnosis of cancer.
Conclusion
We showed that immunization with a VEGF peptide-
conjugate can inhibit tumor growth and metastasis 
in BALB/c mice and might probably increase patient 
survival rate, too.
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